Angiogenesis imaging in myocardial infarction using 68Ga-NOTA- RGD PET: Characterization and application to therapeutic efficacy monitoring in rats

Coronary Artery Disease

Volumn 24, Issue 4, 2013, Pages 303-311

  Eo, Jae Seon ^a,b   Paeng, Jin Chul ^a   Lee, Song ^a   Lee, Yun Sang ^a   Jeong, Jae Min ^a   Kang, Keon Wook ^a   Chung, June Key ^a   Lee, Dong Soo ^a  

^a Seoul National University   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

68Ga; Myocardial infarction; PET; RGD peptide; Therapeutic angiogenesis

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID; ARGINYLGLYCYLASPARTIC ACID; CD68 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; GALLIUM 68; RADIOISOTOPE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOCARDIOGRAPHY; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HISTOPATHOLOGY; IMAGE ANALYSIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; COORDINATION COMPLEXES; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLAST GROWTH FACTOR 2; GALLIUM RADIOISOTOPES; HEART; HETEROCYCLIC COMPOUNDS; HUMANS; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84877048591     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3283608c32     Document Type: Article

References (39)

1. Lassaletta AD, Chu LM, Sellke FW. Therapeutic neovascularization for coronary disease: current state and future prospects. Basic Res Cardiol 2011; 106:897-909.
2. Oostendorp M, Douma K, Wagenaar A, JMGM Slenter, Hackeng TM, van Zandvoort MAMJ, et al. Molecular magnetic resonance imaging of myocardial angiogenesis after acute myocardial infarction. Circulation 2010; 121:775-783.
3. Hashimoto E, Ogita T, Nakaoka T, Matsuoka R, Takao A, Kira Y. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am J Physiol 1994; 267:H1948-H1954.
4. Yanagisawa-Miwa A, Uchida Y, Nakamura F, Tomaru T, Kido H, Kamijo T, et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992; 257:1401-1403.
5. Dobrucki LW, de Muinck ED, Lindner JR, Sinusas AJ. Approaches to multimodality imaging of angiogenesis. J Nucl Med 2010; 51 (Suppl 1): 66S-79S.
6. Dimastromatteo J, Riou LM, Ahmadi M, Pons G, Pellegrini E, Broisat A, et al. In vivo molecular imaging of myocardial angiogenesis using the alpha(v)beta3 integrin-targeted tracer 99mTc-RAFT-RGD. J Nucl Cardiol 2010; 17:435-443.
7. Higuchi T, Bengel FM, Seidl S, Watzlowik P, Kessler H, Hegenloh R, et al. Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res 2008; 78:395-403.
8. Li Z-B, Cai W, Cao Q, Chen K,Wu Z, He L, et al. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med 2007; 48:1162-1171.
9. Harris TD, Kalogeropoulos S, Nguyen T, Liu S, Bartis J, Ellars C, et al. Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother Radiopharm 2003; 18:627-641.
10. Lee K-H, Jung K-H, Song S-H, Kim DH, Lee BC, Sung HJ, et al. Radiolabeled RGD uptake and alphav integrin expression is enhanced in ischemic murine hindlimbs. J Nucl Med 2005; 46:472-478.
11. Sherif HM, Saraste A, Nekolla SG, Weidl E, Reder S, Tapfer A, et al. Molecular imaging of early avb3 integrin expression predicts long-term leftventricle remodeling after myocardial infarction in rats. J Nucl Med 2012; 53:318-323.
12. Gao H, Lang L, Guo N, Cao F, Quan Q, Hu S, et al. PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2. Eur J Nucl Med Mol Imaging 2012; 39:683-692.
13. Jeong JM, Hong MK, Chang YS, Lee Y-S, Kim YJ, Cheon GJ, et al. Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med 2008; 49:830-836.
14. Shetty D, Lee YS, Jeong JM. 68Ga-labeled radiopharmaceuticals for positron emission tomography. Nucl Med Mol Imaging 2010; 44:233-240.
15. Breeman WAP, Verbruggen AM. The 68Ge/68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine? Eur J Nucl Med Mol Imaging 2007; 34:978-981.
16. Kim JH, Lee JS, Kang KW, Lee H-Y, Han S-W, Kim T-Y, et al. Whole-body distribution and radiation dosimetry of (68)Ga-NOTA-RGD, a positron emission tomography agent for angiogenesis imaging. Cancer Biother Radiopharm 2012; 27:65-71.
17. Boodhwani M, Sellke FW. Therapeutic angiogenesis in diabetes and hypercholesterolemia: influence of oxidative stress. Antioxid Redox Signal 2009; 11:1945-1959.
18. Nishida S, Nagamine H, Tanaka Y, Watanabe G. Protective effect of basic fibroblast growth factor against myocyte death and arrhythmias in acute myocardial infarction in rats. Circ J 2003; 67:334-339.
19. Battler A, Scheinowitz M, Bor A, Hasdai D, Vered Z, Di Segni E, et al. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J Am Coll Cardiol 1993; 22:2001-2006.
20. Xiao J, Lv Y, Lin S, Jin L, Zhang Y,Wang X, et al. Cardiac protection by basic fibroblast growth factor from ischemia/reperfusion-induced injury in diabetic rats. Biol Pharm Bull 2010; 33:444-449.
21. Ahn A, Frishman WH, Gutwein A, Passeri J, Nelson M. Therapeutic angiogenesis: a new treatment approach for ischemic heart disease-Part II. Cardiol Rev 2008; 16:219-229.
22. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 285: 1028-1032.
23. Lee EJ, Choi E-K, Kang SK, Kim G-H, Park JY, Kang H-J, et al. N-cadherin determines individual variations in the therapeutic efficacy of human umbilical cord blood-derived mesenchymal stem cells in a rat model of myocardial infarction. Mol Ther 2012; 20:155-167.
24. Yang BY, Jeong JM, Kim YJ, Choi JY, Lee Y-S, Lee DS, et al. Formulation of 68Ga BAPEN kit for myocardial positron emission tomography imaging and biodistribution study. Nucl Med Biol 2010; 37:149-155.
25. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003; 2:131-137.
26. Chang S-A, Lee EJ, Kang H-J, Zhang S-Y, Kim J-H, Li L, et al. Impact of myocardial infarct proteins and oscillating pressure on the differentiation of mesenchymal stem cells: effect of acute myocardial infarction on stem cell differentiation. Stem Cells 2008; 26:1901-1912.
27. Kunisch E, Fuhrmann R, Roth A, Winter R, Lungershausen W, Kinne RW. Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry. Ann Rheum Dis 2004; 63:774-784.
28. Rodriguez-Porcel M, Cai W, Gheysens O, Willmann JK, Chen K, Wang H, et al. Imaging of VEGF receptor in a rat myocardial infarction model using PET. J Nucl Med 2008; 49:667-673.
29. Ahn A, Frishman WH, Gutwein A, Passeri J, Nelson M. Therapeutic angiogenesis: a new treatment approach for ischemic heart disease-part I. Cardiol Rev 2008; 16:163-171.
30. Minami E, Castellani C, Malchodi L, Deem J, Bertko K, Meznarich J, et al. The role of macrophage-derived urokinase plasminogen activator in myocardial infarct repair: urokinase attenuates ventricular remodeling. J Mol Cell Cardiol 2010; 49:516-524.
31. Garbern JC, Minami E, Stayton PS, Murry CE. Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium. Biomaterials 2011; 32: 2407-2416.
32. Laham RJ, Sellke FW, Edelman ER, Pearlman JD,Ware JA, Brown DL, et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999; 100:1865-1871.
33. Ruel M, Laham RJ, Parker JA, Post MJ,Ware JA, Simons M, et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 2002; 124:28-34.
34. Scheinowitz M, Abramov D, Kotlyar A, Savion N, Eldar M. Continuous administration of insulin-like growth factor-I and basic fibroblast growth factor does not affect left ventricular geometry after acute myocardial infarction in rats. Int J Cardiol 1998; 63:217-221.
35. Inagaki M, Kimura A, Miyataka M, Ishikawa K. Basic fibroblast growth factor caused no change in collateral flow or infarct size of acutely-infarcted myocardium in rats. Tohoku J Exp Med 2000; 191:101-111.
36. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002; 105:788-793.
37. Iwakura A, Fujita M, Kataoka K, Tambara K, Sakakibara Y, Komeda M, et al. Intramyocardial sustained delivery of basic fibroblast growth factor improves angiogenesis and ventricular function in a rat infarct model. Heart Vessels 2003; 18:93-99.
38. Tsang BW, Mathias CJ, Green MA. A gallium-68 radiopharmaceutical that is retained in myocardium: 68Ga[(4,6-MeO2sal)2BAPEN] + . J Nucl Med 1993; 34:1127-1131.
39. Dijkgraaf I, Yim C-B, Franssen GM, Schuit RC, Luurtsema G, Liu S, et al. PET imaging of avb3 integrin expression in tumours with 68Ga-labelled mono-, di-and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging 2011; 38:128-137.